|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Segovia-Mendoza M, González-González ME,
Barrera D, Díaz L and García-Becerra R: Efficacy and mechanism of
action of the tyrosine kinase inhibitors gefitinib, lapatinib and
neratinib in the treatment of HER2-positive breast cancer:
Preclinical and clinical evidence. Am J Cancer Res. 5:2531–2561.
2015.PubMed/NCBI
|
|
5
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin Y, Liu AY, Fan C, Zheng H, Li Y, Zhang
C, Wu S, Yu D, Huang Z, Liu F, et al: MicroRNA-33b inhibits breast
cancer metastasis by targeting HMGA2, SALL4 and Twist1. Sci Rep.
5:99952015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xue J, Chen Z, Gu X, Zhang Y and Zhang W:
MicroRNA-148a inhibits migration of breast cancer cells by
targeting MMP-13. Tumour Biol. 37:1581–1590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoo JO, Kwak SY, An HJ, Bae IH, Park MJ
and Han YH: miR-181b-3p promotes epithelial-mesenchymal transition
in breast cancer cells through Snail stabilization by directly
targeting YWHAG. Biochim Biophys Acta. 1863:1601–1611. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao Y, Hu J, Shen Z, Yao R, Liu S, Li Y,
Cong H, Wang X, Qiu W and Yue L: MiR-200b expression in breast
cancer: A prognostic marker and act on cell proliferation and
apoptosis by targeting Sp1. J Cell Mol Med. 19:760–769. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing
C, Gao K, Liu ZH and Yu SJ: miR-429 inhibits migration and invasion
of breast cancer cells in vitro. Int J Oncol. 46:531–538.
2015.PubMed/NCBI
|
|
12
|
Wang W, Li F, Zhang Y, Tu Y, Yang Q and
Gao X: Reduced expression of miR-22 in gastric cancer is related to
clinicopathologic characteristics or patient prognosis. Diagn
Pathol. 8:1022013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ling B, Wang GX, Long G, Qiu JH and Hu ZL:
Tumor suppressor miR-22 suppresses lung cancer cell progression
through post-transcriptional regulation of ErbB3. J Cancer Res Clin
Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang R, Deng L, Zhao L, Li X, Zhang F,
Xia Y, Gao Y, Wang Xa and Sun B: miR-22 promotes HBV-related
hepatocellular carcinoma development in males. Clin Cancer Res.
17:5593–5603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pandey DP and Picard D: miR-22 inhibits
estrogen signaling by directly targeting the estrogen receptor
alpha mRNA. Mol Cell Biol. 29:3783–3790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiong J, Yu D, Wei N, Fu H, Cai T, Huang
Y, Wu C, Zheng X, Du Q, Lin D and Liang Z: An estrogen receptor
alpha suppressor, microRNA-22, is downregulated in estrogen
receptor alpha-positive human breast cancer cell lines and clinical
samples. FEBS J. 277:1684–1694. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen B, Tang H, Liu X, Liu P, Yang L, Xie
X, Ye F, Song C, Xie X and Wei W: miR-22 as a prognostic factor
targets glucose transporter protein type 1 in breast cancer. Cancer
Lett. 356:410–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel JB, Appaiah HN, Burnett RM,
Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S,
Steeg P, et al: Control of EVI-1 oncogene expression in metastatic
breast cancer cells through microRNA miR-22. Oncogene.
30:1290–1301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu D, Takeshita F, Hino Y, Fukunaga S,
Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A,
et al: miR-22 represses cancer progression by inducing cellular
senescence. J Cell Biol. 193:409–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kong LM, Liao CG, Zhang Y, Xu J, Li Y,
Huang W, Zhang Y, Bian H and Chen ZN: A regulatory loop involving
miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer
invasion and metastasis. Cancer Res. 74:3764–3778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shao P, Liu Q, Maina PK, Cui J, Bair TB,
Li T, Umesalma S, Zhang W and Qi HH: Histone demethylase PHF8
promotes epithelial to mesenchymal transition and breast
tumorigenesis. Nucleic Acids Res. Nov 29–2016.(Epub ahead of
print).
|
|
22
|
Koufaris C, Valbuena GN, Pomyen Y,
Tredwell GD, Nevedomskaya E, Lau CH, Yang T, Benito A, Ellis JK and
Keun HC: Systematic integration of molecular profiles identifies
miR-22 as a regulator of lipid and folate metabolism in breast
cancer cells. Oncogene. 35:2766–2776. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Damavandi Z, Torkashvand S, Vasei M,
Soltani BM, Tavallaei M and Mowla SJ: Aberrant expression of breast
development-related microRNAs, miR-22, miR-132 and miR-212, in
breast tumor tissues. J Breast Cancer. 19:148–155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pandey AK, Zhang Y, Zhang S, Li Y,
Tucker-Kellogg G, Yang H and Jha S: TIP60-miR-22 axis as a
prognostic marker of breast cancer progression. Oncotarget.
6:41290–41306. 2015.PubMed/NCBI
|
|
25
|
Lin L, Zheng X, Qiu C, Dongol S, Lv Q,
Jiang J, Kong B and Wang C: SIRT1 promotes endometrial tumor growth
by targeting SREBP1 and lipogenesis. Oncol Rep. 32:2831–2835.
2014.PubMed/NCBI
|
|
26
|
Li L and Bhatia R: Role of SIRT1 in the
growth and regulation of normal hematopoietic and leukemia stem
cells. Curr Opin Hematol. 22:324–329. 2015.PubMed/NCBI
|
|
27
|
Qu Y, Zhang J, Wu S, Li B, Liu S and Cheng
J: SIRT1 promotes proliferation and inhibits apoptosis of human
malignant glioma cell lines. Neurosci Lett. 525:168–172. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ohanna M, Bonet C, Bille K, Allegra M,
Davidson I, Bahadoran P, Lacour JP, Ballotti R and Bertolotto C:
SIRT1 promotes proliferation and inhibits the senescence-like
phenotype in human melanoma cells. Oncotarget. 5:2085–2095. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Elangovan S, Ramachandran S, Venkatesan N,
Ananth S, Gnana-Prakasam JP, Martin PM, Browning DD, Schoenlein PV,
Prasad PD, Ganapathy V and Thangaraju M: SIRT1 is essential for
oncogenic signaling by estrogen/estrogen receptor a in breast
cancer. Cancer Res. 71:6654–6664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao YW, Li YC, Wan GX, Du XM and Li F:
Clinicopathological and prognostic role of SIRT1 in breast cancer
patients: A meta-analysis. Int J Clin Exp Med. 8:616–624.
2015.PubMed/NCBI
|
